-Search query
-Search result
Showing 1 - 50 of 105 items for (author: moriya & t)
EMDB-38986:
P-glycoprotein in complex with UIC2 Fab and triple elacridar molecules in LMNG detergent
Method: single particle / : Hamaguchi-Suzuki N, Adachi N, Moriya T, Kawasaki M, Suzuki K, Anzai N, Senda T, Murata T
EMDB-38987:
P-glycoprotein in complex with UIC2 Fab and triple elacridar molecules in nanodisc
Method: single particle / : Hamaguchi-Suzuki N, Adachi N, Moriya T, Kawasaki M, Suzuki K, Anzai N, Senda T, Murata T
PDB-8y6h:
P-glycoprotein in complex with UIC2 Fab and triple elacridar molecules in LMNG detergent
Method: single particle / : Hamaguchi-Suzuki N, Adachi N, Moriya T, Kawasaki M, Suzuki K, Anzai N, Senda T, Murata T
PDB-8y6i:
P-glycoprotein in complex with UIC2 Fab and triple elacridar molecules in nanodisc
Method: single particle / : Hamaguchi-Suzuki N, Adachi N, Moriya T, Kawasaki M, Suzuki K, Anzai N, Senda T, Murata T
EMDB-34741:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-34742:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11 focused on RBD and NIV-11 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-8hgl:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-8hgm:
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33820:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 focused on RBD and NIV-8 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33821:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33822:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33823:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 focused on RBD and NIV-10 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33824:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33825:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33826:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 3)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33827:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 focused on RBD and NIV-13 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33828:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33829:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33830:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 3)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-7yh6:
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-8
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-7yh7:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33643:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab816
Method: single particle / : Uchikubo T, Shirouzu M
EMDB-33644:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab803
Method: single particle / : Uchikubo T, Shirouzu M
PDB-7y6l:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab816
Method: single particle / : Uchikubo T, Shirouzu M
PDB-7y6n:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab803
Method: single particle / : Uchikubo T, Shirouzu M
EMDB-33065:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab765
Method: single particle / : Kamada K, Shirouzu M
EMDB-33066:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab712
Method: single particle / : Kamada K, Shirouzu M
EMDB-33067:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab709
Method: single particle / : Kamada K, Shirouzu M
EMDB-33068:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab847
Method: single particle / : Kamada K, Shirouzu M
PDB-7x93:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab765
Method: single particle / : Kamada K, Shirouzu M
PDB-7x94:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab712
Method: single particle / : Kamada K, Shirouzu M
PDB-7x95:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab709
Method: single particle / : Kamada K, Shirouzu M
PDB-7x96:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab847
Method: single particle / : Kamada K, Shirouzu M
EMDB-35080:
Far-red light-harvesting complex of Antarctic alga Prasiola crispa
Method: single particle / : Kosugi M, Kawasaki M, Shibata Y, Moriya T, Adachi N, Senda T
PDB-8hw1:
Far-red light-harvesting complex of Antarctic alga Prasiola crispa
Method: single particle / : Kosugi M, Kawasaki M, Shibata Y, Moriya T, Adachi N, Senda T
EMDB-33289:
Cryo-EM structure of mTIP60-Ba (metal-ion induced TIP60 (K67E) complex with barium ions
Method: single particle / : Ohara N, Kawakami N, Arai R, Adachi N, Moriya T, Kawasaki M, Miyamoto K
PDB-7xm1:
Cryo-EM structure of mTIP60-Ba (metal-ion induced TIP60 (K67E) complex with barium ions
Method: single particle / : Ohara N, Kawakami N, Arai R, Adachi N, Moriya T, Kawasaki M, Miyamoto K
EMDB-33059:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab354
Method: single particle / : Kamada K, Shirouzu M
EMDB-33060:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab159
Method: single particle / : Kamada K, Shirouzu M
EMDB-33061:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab188
Method: single particle / : Kamada K, Shirouzu M
EMDB-33062:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab326
Method: single particle / : Kamada K, Shirouzu M
EMDB-33063:
The SARS-CoV-2 receptor binding domain bound with an Fv-clasp form of a human neutralizing antibody Ab496
Method: single particle / : Kamada K, Shirouzu M
EMDB-33064:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab445
Method: single particle / : Kamada K, Shirouzu M
PDB-7x8w:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab354
Method: single particle / : Kamada K, Shirouzu M
PDB-7x8y:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab159
Method: single particle / : Kamada K, Shirouzu M
PDB-7x8z:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab188
Method: single particle / : Kamada K, Shirouzu M
PDB-7x90:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab326
Method: single particle / : Kamada K, Shirouzu M
PDB-7x91:
The SARS-CoV-2 receptor binding domain bound with an Fv-clasp form of a human neutralizing antibody Ab496
Method: single particle / : Kamada K, Shirouzu M
PDB-7x92:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab445
Method: single particle / : Kamada K, Shirouzu M
EMDB-32381:
Trichodesmium erythraeum cyanophycin synthetase 1 (TeCphA1)
Method: single particle / : Kawasaki M, Miyakawa T, Yang J, Adachi N, Fujii A, Miyauchi Y, Muramatsu T, Moriya T, Senda T, Tanokura M
Pages: